Sponsored by

Poster Number Index
Click on one of the following number ranges below to display a list of posters.
Click the checkbox next to each item to bookmark.

101 – 200 | 201 – 300 | 301 – 400 | 401 – 500 | 501 – 600 | 601 – 700 | 701 – 800
801 – 900 | 901 – 1000 | 1001 – 1100 | 1101 – 1200 | 2001 – 2100 | 2101 – 2200 | 3001 – 3100
3101 – 3200 | 4001 – 4100 | 4101 – 4200 | 5001 – 5100 | 5101 – 5200 | 6001 – 6100 | 6101 – 6152

  [3001] Identification of high-risk lesions through automated natural language processing (NLP) of pathology reports.
  [3002] Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?
  [3005] A UK NEQAS ring study evaluating observer variation in the diagnosis of HER2 amplification using the Kreatech™ HER2 FISH probe.
  [3006] Clinical significance of the entity 'flat epithelial atypia' on core needle biopsies of breast.
  [3008] “Polysomy 17” by FISH for HER2 in breast cancer is a misnomer: results of chromosome 17 analysis by array comparative genomic hybridization.
  [3010] Improved methods of detection, and prognostic significance, of vascular invasion in breast cancer.
  [3011] Usefulness of intraoperative touch smear cytology in breast-conserving surgery.
  [3012] Intra operative determination of axillary node metastasis by RT PCR: experience on 50 breast cancer patients.
  [3013] Quality improvement analysis of HER2 FISH testing in breast cancer in response to the new ASCO/CAP guidelines.
  [3014] Are there preoperative predictors for invasive disease in DCIS?
  [3017] Effects of short-time tamoxifen therapy on breast cancer apoptosis and cell cycle regulators.
  [3018] Molecular analysis of the selective pro-apoptotic effect of the herbal extract BN108 on breast cancer cells.
  [3020] Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
  [3024] Computational inference of gene expression signatures differentiating between breast cancers responsive or resistant to letrozole.
  [3025] Activated c-Src (Y215) kinase expression predicts for early relapse on tamoxifen in human breast cancer.
  [3026] Mammostrat® as a tool to stratify patients at risk of recurrence during endocrine therapy.
  [3027] Overexpression of CD44 in acquired endocrine resistant breast cancer modulates erbB activity and promotes an invasive phenotype.
  [3028] Overexpression of L1CAM accompanies acquired endocrine resistance and is associated with the development of an aggressive cell phenotype.
  [3029] Control of luminal type A intrinsic subtype enriched transcription factor network by insulin: implications of diabetes on breast cancer classification.
  [3030] Proteomics analysis of tissue samples obtained before and during letrozole treatment in postmenopausal patients with locally advanced breast cancer.
  [3031] Lapatinib can activate or supress estrogen receptor (ER) signaling in cell models of endocrine resistant breast cancer.
  [3032] Coassociation of ERα and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence.
  [3034] The developmental protein HOXc11 as a mediator of endocrine resistance in breast cancer.
  [3036] Key elements for discriminating selective estrogen receptor modulators and selective receptor estrogen down regulators: a molecular approach to classify antiestrogens.
  [3037] Expression of ER-a36, a novel variant of estrogen receptor a, and resistance to tamoxifen treatment in breast cancer.
  [3041] Role of progesterone receptor extra-nuclear signaling in mammary epithelial cell differentiation and breast cancer progression.
  [3042] MicroRNA-206 expression is down-regulated in estrogen receptor a-positive human breast cancer.
  [3043] Outcomes of triple negative breast cancer in African-Americans vs. Caucasians: a community-based study.
  [3045] Deletion of STAT5 prevents HER2/Neu/ErbB2-induced mammary tumor development.
  [3047] Interactive effects of low-dose estradiol and tamoxifen on the postmenopausal primate endometrium and mammary gland.
  [3048] Insulin like growth factor in breast cancer subtypes.
  [3049] Associations between estrogen receptor (ER) Alpha expression levels and ER genotypes.
  [3052] Normal breast tissue cells from breast cancer patients express epidermal growth factor receptor HER1-4 protein concentrations characteristic for cancer cells.
  [3053] Comparison between HER-2/neu, estrogen and progesterone receptors in primary breast carcinomas and matched lymph node metastases.
  [3054] Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells.
  [3056] The antitumorgenic actions of estrogen receptor beta in breast cancer cells.
  [3057] Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies.
  [3058] Does the recurrence of pregnancy-associated breast cancer during subsequent pregnancy 10 years after mastectomy support the unique hormonal milieu of pregnancy as a cause of tumorigenesis? A case and literature review.
  [3060] Activity and mechanism of action of histone deacetylase inhibitors in trastuzumab resistant breast cancer.
  [3063] Synthetic lethality when combining phosphoinositide 3-kinase alpha and beta catalytic subunit-directed RNAi and estrogen deprivation for estrogen receptor positive breast cancer: implications for clinical trial design with pharmacological inhibitors.
  [3066] Inhibiting nicastrin (NCT) stabilizes expression of e-cadherin and has potential in inducing mesenchymal to epithelial transition in breast cancer (BC).
  [3068] Blocking internalization of pBP1, a secreted homeoprotein, kills breast cancer cells but not normal breast epithelial cells.
  [3071] Molecular mechanisms for leptin regulation of VEGF in breast cancer cells.
  [3072] Rapamycin-regulated gene expression signature determines prognosis in breast cancer.
  [3073] Protein tyrosine kinase 6 (PTK6): a new/potential therapy target in breast cancer?
  [3075] Netrin-1: a promising therapeutic target in metastatic breast cancer. Expression analysis in localized and metastatic breast tumors and preclinical validation.
  [3076] The RNA binding protein HuR/ELAV1 regulates the estrogen receptor and epidermal growth factor receptor beta expression in BT 474 cells.
  [3077] Cytotoxic effects of crystal proteins from Bacillus thuringiensis against breast cancer cells.
  [3078] Synergisitic inhibition of DNA repair by combining ß-lapachone with Nu7026 as a strategy for killing primary and metastatic breast cancers.
  [3079] Role of tissue factor, caveolin-1 and tissue factor pathway inhibitor in the invasive, angiogenic and procoagulative potential of breast cancer cells.
  [3080] Nano-gossypin, a novel cdk2/VEGF inhibitor formulation against breast cancer.
  [3081] The estrogen metabolite 2-methoxyestradiol inhibits the progesterone mediated increase in tissue factor, angiogenesis and invasive potential of breast cancer cells.
  [3084] Epstein-Barr virus (EBV) in fine needle aspirates containing inflammatory breast cancer cells.
  [3086] Human papillomavirus in breast carcinomas of Korean women.
  [3088] Is the biology of breast cancer changing? A study of hormone receptor status and grade of breast cancers 1984-1986 and 1996-97.
  [3089] Cytochrome P450 2D6 variants and their association with breast cancer survival.
  [3090] Effect of protein phosphatase 2A subunit gene haplotypes and proliferative breast disease on breast cancer risk.
  [3091] Impact of BRCA mutation status on the clinical phenotype and survival of hereditary breast cancer.
  [3094] Gene associations and risk of breast cancer.
  [3095] Prophylactic surgical uptake in a cohort of BRCA carriers: an Irish perspective.
  [3097] BRCA mutation in Chinese population: results from the Hong Kong hereditary and high risk breast cancer programme (HRBCP) and the Hong Kong hereditary and high risk breast cancer family registry.
  [3098] The new understanding of two-sided role of glutathione S-transferase M1 in breast cancer susceptibility.
  [3099] HER2/ER subtypes associated with patient and tumor factors and predicted survival among participants in a retrospective breast cancer cohort study in Southern California.
  [3100] Preference for breast cancer risk reduction hormonal therapy in women age 50-69 years attending screening mammography.

 
 

Poster Sessions | Support | FAQ | Privacy Policy

San Antonio Breast Cancer Symposium
7703 Floyd Curl Dr. Mail Code 8224
San Antonio, TX 78229 USA
http://www.sabcs.org
Technical Support • © 2010 Marathon Multimedia, a Learner’s Digest International business. • All rights reserved